208 related articles for article (PubMed ID: 37715546)
1. Copper homeostasis and cuproptosis in cancer immunity and therapy.
Liu WQ; Lin WR; Yan L; Xu WH; Yang J
Immunol Rev; 2024 Jan; 321(1):211-227. PubMed ID: 37715546
[TBL] [Abstract][Full Text] [Related]
2. Stimulus-Responsive Copper Complex Nanoparticles Induce Cuproptosis for Augmented Cancer Immunotherapy.
Hu F; Huang J; Bing T; Mou W; Li D; Zhang H; Chen Y; Jin Q; Yu Y; Yang Z
Adv Sci (Weinh); 2024 Apr; 11(13):e2309388. PubMed ID: 38269649
[TBL] [Abstract][Full Text] [Related]
3. Copper homeostasis and cuproptosis in health and disease.
Chen L; Min J; Wang F
Signal Transduct Target Ther; 2022 Nov; 7(1):378. PubMed ID: 36414625
[TBL] [Abstract][Full Text] [Related]
4. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma.
Ozkan E; Bakar-Ates F
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17663-17670. PubMed ID: 37843555
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
[TBL] [Abstract][Full Text] [Related]
7. Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.
Abdullah KM; Kaushal JB; Takkar S; Sharma G; Alsafwani ZW; Pothuraju R; Batra SK; Siddiqui JA
Heliyon; 2024 Mar; 10(5):e27496. PubMed ID: 38486750
[TBL] [Abstract][Full Text] [Related]
8. Copper-coordinated nanoassemblies based on photosensitizer-chemo prodrugs and checkpoint inhibitors for enhanced apoptosis-cuproptosis and immunotherapy.
Liang W; Han C; Zhang D; Liu C; Zhu M; Xu F; Fang C; Zhang S; Liu C; Li Y
Acta Biomater; 2024 Feb; 175():341-352. PubMed ID: 38122883
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.
Feng Y; Yang Z; Wang J; Zhao H
Cell Commun Signal; 2024 May; 22(1):249. PubMed ID: 38693584
[TBL] [Abstract][Full Text] [Related]
10. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis: Mechanism, role, and advances in urological malignancies.
Wu J; He J; Liu Z; Zhu X; Li Z; Chen A; Lu J
Med Res Rev; 2024 Jul; 44(4):1662-1682. PubMed ID: 38299968
[TBL] [Abstract][Full Text] [Related]
12. Copper homeostasis and cuproptosis in mitochondria.
Tian Z; Jiang S; Zhou J; Zhang W
Life Sci; 2023 Dec; 334():122223. PubMed ID: 38084674
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
14. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
[TBL] [Abstract][Full Text] [Related]
15. A biomimetic cuproptosis amplifier for targeted NIR-II fluorescence/photoacoustic imaging-guided synergistic NIR-II photothermal immunotherapy.
Dai Y; Zhu L; Li X; Zhang F; Chen K; Jiao G; Liu Y; Yang Z; Guo Z; Zhang B; Shen Q; Zhao Q
Biomaterials; 2024 Mar; 305():122455. PubMed ID: 38160626
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer.
Chu B; Wang Y; Yang J; Dong B
Aging (Albany NY); 2023 Dec; 15(23):14422-14444. PubMed ID: 38078879
[TBL] [Abstract][Full Text] [Related]
17. A tumor microenvironment-responsive core-shell tecto dendrimer nanoplatform for magnetic resonance imaging-guided and cuproptosis-promoted chemo-chemodynamic therapy.
Ni C; Ouyang Z; Li G; Liu J; Cao X; Zheng L; Shi X; Guo R
Acta Biomater; 2023 Jul; 164():474-486. PubMed ID: 37040813
[TBL] [Abstract][Full Text] [Related]
18. Research progress in cuproptosis in liver cancer.
Chen L; Liu D; Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
Song Q; Zhou R; Shu F; Fu W
Front Immunol; 2022; 13():958368. PubMed ID: 35990642
[TBL] [Abstract][Full Text] [Related]
20. Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy.
Lu X; Chen X; Lin C; Yi Y; Zhao S; Zhu B; Deng W; Wang X; Xie Z; Rao S; Ni Z; You T; Li L; Huang Y; Xue X; Yu Y; Sun W; Shen X
Adv Sci (Weinh); 2024 May; 11(18):e2309984. PubMed ID: 38430531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
